Implementation of Indication-Based Hepatitis C Formulary Results In Greater Access to Care and Lower Drug Costs

BACKGROUND
Hepatitis C virus (HCV) is a leading cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC), as well as the most common indication for liver transplantation in many countries.1 HCV is classified into seven different genotypes, with genotype 1 being the most prevalent worldwide.2 In the United States, about 70% of individuals infected with HCV have genotype 1, 16% have genotype 2, 12% have genotype 3, and less than 1% have genotypes 4 through 7.3

HCV is a blood borne pathogen, and most newly-infected individuals in the United States contract the disease due to sharing needles or other equipment to inject drugs. Prior to 1992, the national blood supply was not routinely screened for HCV and, as a result, many people who received blood transfusions before that time were infected.4

To continue reading, please fill out the form below to download the WellDyneRx clinical white paper.